Few people understand what makes, say, your MoA different or why your clinical trial has a better chance. We get it. And we can make it intelligible thru words, pictures and, yes, research.
We cringe when IR and PR firms recycle the same reports every week. We do a lot. So we have a lot to report. Including what worked, what didn’t, and what we’re going to do about it.
IP is important. For our clients, it is their science and technology. For our team, we deploy our trademarked SPEAR(TM) technology to give us an edge over traditional marketing and PR firms.
Most firms are a one-and-done mentality. We overdeliver on content, the number of posts created and the way is distributed, From syndicated placement on Accesswire, Google Finance, WSJ and dozens more, to targeted social in all media. Ask for our stats.
We have lists–especially a proprietary 1 million + investors database categorized by interest and investment history. You have lists. We acquire other lists. And our competitors? They have a few names in their contacts, mostly cronies and ex-employers. We reach new investors in new ways.
Our work with individual clients and clients with large company rosters gives us data and insights at a scale much larger firms just can’t achieve, especially in an omnichannel media world.
Everyone has email lists. And everyone gets <1% open rate. But our lists get >10% connection rate. We do this well because we reach people in relevant ways.
From an unsung underdog to an uplisted rising star with a robust pipeline and significant runway.
Long-standing relationships matter, especially in the biotech beatdown and a shift from institutional to retail loyalists.
Working with a VC with science-based portfolio companies gives us insights for companies of all sizes.